ArticleJournal of the American Heart Association2023
Large-Scale Metabolomics and the Incidence of Cardiovascular Disease.
Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 45 citations in OpenAlex.
- Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy.The Journal of clinical endocrinology and metabolism · 2024Trial
- Metabolomic Profiling Delineates Stage-Associated Metabolic Remodelling in Cardiovascular-Kidney-Metabolic Syndrome.Diabetes/metabolism research and reviews · 2026Article
- Metabolomic signature of ultra-processed foods and cardiovascular morbidity and mortality.Clinical nutrition (Edinburgh, Scotland) · 2026Article
- Robust Metabolomics Data Normalization across Scales and Experimental Designs.Analytical chemistry · 2026Article
- Circulating imidazole propionate and coronary heart disease risk: interplay between histidine intake, fiber, and gut microbiome.BMC medicine · 2026Article
- A blood-based metabolomics study of cardiovascular diseases in Swedish twins reveals apolipoprotein B biology as important for myocardial infarction.GeroScience · 2026Article
- Plasma and pericardial fluid metabolomic signatures of patients with ischemic heart disease.Communications medicine · 2026Article
- Metabolomic signatures connect and mediate sedentary time-driven mortality risk in patients with cardiovascular disease.Frontiers in sports and active living · 2026Article
- Article
- Who will be our adult congenital heart disease patient tomorrow?European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Longitudinal, Intra-Individual Stability of Untargeted Plasma and Cerebrospinal Fluid Metabolites.Metabolites · 2025Article
- Longitudinal, intra-individual stability of untargeted plasma and cerebrospinal fluid metabolites.medRxiv : the preprint server for health sciences · 2025Article
- Metabolomics Signatures of Atherosclerosis in Cardiovascular Disease: A Narrative Systematic Review.Journal of clinical medicine · 2025Review
- Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease.Journal of the American Heart Association · 2025Article
- Early changes in urineMetabolomics : Official journal of the Metabolomic Society · 2025Article
- Watercress (Life (Basel, Switzerland) · 2025Review
- N-Lactoyl Amino Acids: Emerging Biomarkers in Metabolism and Disease.Diabetes/metabolism research and reviews · 2025Review
- Assessing the potential causal effects of 1099 plasma metabolites on 2099 binary disease endpoints.Nature communications · 2025Article
- Pathway level metabolomics analysis identifies carbon metabolism as a key factor of incident hypertension in the Estonian Biobank.Scientific reports · 2025Article
- Advancements in omics technologies: Molecular mechanisms of acute lung injury and acute respiratory distress syndrome (Review).International journal of molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The study aimed to show the relationship between a large number of circulating metabolites and subsequent cardiovascular disease (CVD) and subclinical markers of CVD in the general population. Methods and Results In 2278 individuals free from CVD in the EpiHealth study (aged 45-75 years, mean age 61 years, 50% women), 790 annotated nonxenobiotic metabolites were measured by mass spectroscopy (Metabolon). The same metabolites were measured in the PIVUS (Prospective Investigation of Vasculature in Uppsala Seniors) study (n=603, all aged 80 years, 50% women), in which cardiac and carotid artery pathologies were evaluated by ultrasound. During a median follow-up of 8.6 years, 107 individuals experienced a CVD (fatal or nonfatal myocardial infarction, stroke, or heart failure) in EpiHealth. Using a false discovery rate of 0.05 for age- and sex-adjusted analyses and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.